Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 1, 2013, Pages 3-13

  Gandhi, Sonia ^a   Srinivasan, B P ^a   Akarte, Atul Sureshrao ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

aliskiren; diabetic nephropathy; Direct renin inhibitor; glomerular filtration rate markers; glomerulosclerosis; insulin resistance

Indexed keywords

ADIPONECTIN; ALBUMIN; ALISKIREN; BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; ERYTHROPOIETIN; GLUCOSE; INSULIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALBUMIN BLOOD LEVEL; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; LIVER; NONHUMAN; OSMOTIC MINIPUMP; RAT; SKELETAL MUSCLE; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

AMIDES; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DNA FRAGMENTATION; EXTRACELLULAR MATRIX; FUMARATES; GLOMERULAR FILTRATION RATE; GLUCOSE TRANSPORTER TYPE 2; GLUCOSE TRANSPORTER TYPE 4; HEMODYNAMICS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIVER; MICE; MUSCLES; RATS; RATS, WISTAR; ROC CURVE;

EID: 84874069345     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312452766     Document Type: Article

References (75)

1. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006 ; 116: 288-296
2. Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008 ; 358: 2503-2505
3. Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999 ; 10: 2382-2391
4. Skeggs T, Kahn JR, Lentz K, et al. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957 ; 106: 439-453
5. Riccioni G, Vitulano N, Zanasi A, et al. Aliskiren: beyond blood pressure reduction. Expert Opin Investig Drugs. 2010 ; 19: 1265-1274
6. Cohen NC. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. Chem Biol Drug Des. 2007 ; 70: 557-565
7. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 ; 25: 217-226
8. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertens. 2003 ; 42: 1137-1143
9. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007 ; 370: 221-229
10. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertens. 2005 ; 46: 569-576
11. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007 ; 50: 2398-2404
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 ; 359: 995-1003
13. Kjeldsen SE, Julius S, Mancia G, et al. VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006 ; 24: 1405-1412
14. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. Meta-analysis of randomized clinical trials. Diabetes Metab. 2004 ; 30: 487-496
15. Lua T, Carlsson PO, Leung PS. Evidence of a local angiotensingenerating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia. 2004 ; 47: 240-248
16. Chu KY, Lau T, Carlsson PO, et al. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006 ; 55: 367-374
17. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertens. 2003 ; 42: 76-81
18. Yoshihiko H, Takuya I, Kaoru Y, et al. Effects of Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) on hyperglycemia in streptozotocin-induced diabetic rats. Biol Pharm Bull. 2007 ; 30: 1015-1020
19. Nyathani HK, Srirangam P, Jinugu VS. Renoprotective effects of combined aliskiren and valsartan in diabetic nephropathy in rats. Intl J Pharm Sci Rev Res. 2011 ; 6: 152-158
20. Arulmozhi DK, Veeranjaneylu A, Bodhankar SL. Neonatal streptozotocin induced rat model of type 2 diabetes mellitus: a glance. Ind J Pharmacol. 2004 ; 36: 217-221
21. Matsuno T, Sasaki H, Nakagawa K. Fas antigen expression and apoptosis in kidney allografts. Transplant Proc. 1997 ; 29: 177-178
22. Weir GC, Clore EE, Zmachinski CJ, et al. Islet secretion in new experimental model of non-insulin dependent diabetes. Diab Metab Rev. 1981 ; 30: 590-594
23. Daniel JR. β-cell in type 2 diabetes mellitus. Diabetes. 1991 ; 40: 116-180
24. Masiello P, Broca C, Gross R, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes. 1998 ; 47: 224-229
25. Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kid Intl. 1998 ; 154: 343-352
26. Lakshmanan AP, Thandavarayan RA, Watanabe K, et al. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. Mol Cell Endocrinol. 2012 2011 ; 348: 104-111
27. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertens. 2007 ; 49: 276-284
28. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 ; 358: 2433-2446
29. Riccioni G. Aliskiren in the treatment of hypertension and organ damage. Cardiovasc Ther. 2011 ; 29: 77-87
30. Peñacarrillo VM, Jesús P, Araceli R, et al. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine. 2001 ; 15: 241-248
31. Habibi J, Whaley-Connell A, Hayden MR, et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinol. 2008 ; 149: 5643-5653
32. Scherer PE, Bickel PE, Kotler M, et al. Cloning of cell-speciïc secreted and surface proteins by subtractive antibody screening. Nat Biotechnol. 1998 ; 16: 581-586
33. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002 ; 8: 1288-1295
34. Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinol. 2009 ; 150: 2561-2568
35. Snehalatha C, Mukesh B, Simon M, et al. Plasma adiponectin as an independent predictor of type 2 diabetes especially in Asian Indians. Diabetes Care. 2003 ; 26: 3226-3229
36. Okamoto Y, Arita M, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metabol Res. 2000 ; 32: 47-50
37. Fiorentino AD, Cianchetti S, Celi A, et al. Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS. JRAAS. 2010 ; 11: 243-247
38. Nakamaki S, Satoh H, Kudoh A, et al. Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats. Exp Biol Med (Maywood). 2011 ; 236: 614-620
39. De Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004 ; 110: 921-927
40. De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kid Intl. 2004 ; 65: 2309-2320
41. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kid Dis. 2005 ; 45: 281-287
42. Parving HH. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia. 1998 ; 41: 745-759
43. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007 ; 18: 1540-1546
44. Grieve KA, Balazs N, Comper WD. Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem. 2001 ; 47: 1717-1719
45. Kaysen G, Don BR. Serum albumin concentration and chronic kidney disease. US Nephrol. 2010 ; 5: 20-27
46. Roy S, Sen C K, Kobuchi H, et al. Antioxidant regulation of phorbol ester-induced adhesion of human Jurkat T-cells to endothelial cells. Free Radic Biol Med. 1998 ; 25: 229-241
47. Allison AE. Proteinuria and interstitial injury. Nephrol Dial Transplant. 2004 ; 19: 277-281
48. Persson F, Lewis JB, Lewis EJ, et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol. 2011 ; 6: 1025-1031
49. Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new class of antihypertensive drug. Am J Med. 2008 ; 121: 265-271
50. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004 ; 15: 3126-3133
51. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 ; 111: 1012-1018
52. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007 ; 49: 1157-1163
53. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens. 2007 ; 20: 587-597
54. Sonta, Inoguchi T, Matsumoto S, et al. In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker. Biochem Biophys Res Commun. 2005 ; 330: 415-422
55. Chen H, Qing Li, Yu-qian Bao, et al. The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression. Acta Pharmacol Sin. 2009 ; 30: 242-250
56. Huang Y, Noble NA, Zhang J, et al. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kid Intl. 2007 ; 72: 45-52
57. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kid Intl. 2006 ; 69: 105-113
58. Johnston CI, Risvanis J, Naitoh M, et al. Mechanism of progression of renal disease - current hemodynamic concepts. J Hypertens. 1998 ; 16: S3 - S7
59. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kid Intl. 1997 ; 52: S107 - S110
60. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kid Intl. 1983 ; 23: 647-655
61. Advani A, Kelly DJ, Advani SL, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Nat Acad Sci U S A. 2007 ; 104: 14448-14453
62. Izuhara Y, Nangaku M, Inagi R, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 ; 16: 3631-3641
63. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003 ; 228: 1-14
64. Perrone RD, Madias NE, Levey AS. Serum creatine as an index of renal function. New insights into an old concept. Clin Chem. 1992 1933 ; 38 :
65. Kurien BT, Everds NE, Scoïeld RH. Experimental animal urine collection: a review. Laborat Anim. 2004 ; 38: 333-361
66. David J. Evaluation of renal function. Nephrology. 2005 ; 10: 133-176
67. Filler G, Witt I, Priem F, et al. Are cystatin c and b2-microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects?. Clin Chem. 1997 1997 ; 43 :
68. Kazama JJ, Kutsuwada K, Ataka K, et al. Serum cystatin c reliably detects renal dysfunction in patients with various renal diseases. Nephron. 2002 ; 91: 13-20
69. Westhuyzen J. Review: Cystatin c: a promising marker and predictor of impaired renal function. Annals Clin Lab Sci. 2006 ; 36: 387-394
70. Tenstad O, Roald AB, Grubb A, et al. Renal handing of radiolabelled human cystatin c in the rat. Scand J Clin Lab Invest. 1996 ; 56: 409-414
71. Fliser D, Ritz E. Serum cystatin c concentration as a marker of renal dysfunction in the elderly. Am J Kid Dis. 2001 ; 37: 79-83
72. Winchester JF, Salsberg JA, Levin NW. Beta-2 microglobulin in ESRD: an in-depth review. Adv Renal Replace Ther. 2003 ; 10: 279-309
73. Lapsley MPA, Sansom CT, Marlow FV, et al. Beta2-glycoprotein- 1 (apolipoprotein H) excretion in chronic renal tubular disorders: comparison with other protein markers of tubular malfunction. J Clin Pathol. 1991 ; 44: 812-816
74. Byung WL, Sung HI, Moon GC, et al. The comparison of cystatin c and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy. Diab Res Clin Pract. 2007 ; 78: 428-434
75. Jernberg T, Lindahl B, James S, et al. Cystatin c. A novel predictor of outcome in suspected or confirmed non-ST elevation acute coronary syndromes. Circulation. 2004 ; 110: 2342-2348